American Society of Hirudotherapy

Hirudin-Like Factor 4 (HLF4, European Medicinal Leeches)

Paralogous hidden hirudin-like factor in H. medicinalis / verbana / orientalis whose native form has minimal anticoagulant activity — Müller 2020 structure-activity engineering.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 28, 2026 · ASH Editorial · based on the books

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding

Clinical translation limit

HLF4's engineered anticoagulant activity in vitro does NOT establish clinical efficacy. No FDA-approved derivative.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Source species
Hirudo medicinalis / verbana / orientalis
Discovered
2020 · Müller C et al.

Biological Targets

  • → thrombin (weak native; engineered enhancement possible via N-terminal + central-domain modifications)

Key Citations

  1. Müller C et al. (2020), Parasitol Res · PMID 32363441

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.